Jilbaab Pharmaceutical Import Profile — Maldives (DGFT 2022–2026)

Name: Jilbaab Pharmaceutical Import Records from India — 2 Products, $224.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Jilbaab — Pharmaceutical Importer Profile (2026) | 2 Products, $224.0K Trade | TransData Nexus

Jilbaab

Pharmaceutical Importer · Maldives · Brand Names & OTC Products Focus · $224.0K Total Trade · DGFT Verified

Jilbaab is a pharmaceutical importer based in Maldives with a total trade value of $224.0K across 2 products in 1 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Jilbaab sources from 2 verified Indian suppliers, with Krishna Marketing accounting for 99.8% of imports.

Jilbaab — Import Portfolio & Supplier Network

Jilbaab import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Jilbaab?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Krishna Marketing	$1.3M	110	99.8%
Mode Creation	$1.9K	7	0.2%

Jilbaab sources from 2 verified Indian suppliers across 66 distinct formulations. The sourcing is highly concentrated — Krishna Marketing accounts for 99.8% of total imports, indicating a strategic single-source relationship.

What Formulations Does Jilbaab Import?

Formulation	Value	Ships
Vicks vaporub 25GM	$101.6K	5
Ap pain balm 12GM	$101.2K	3
Monisons pain balm 45GM	$100.9K	3
Amrutanjan strong 25ML	$96.6K	3
Amrutanjan yellow 25ML	$96.6K	3
Amrutanjan maha strong 25ML	$96.6K	3
Vicks baby rub 25ML	$71.9K	3
Iodex balm 20GM	$71.9K	3
Navaratan oil 500ML	$65.7K	3
Moov spray 30ML	$61.6K	3
Moov gel 30GM	$61.6K	3
Navaratan oil 300ML	$41.1K	3
Tiger balm strong 21GM	$41.1K	3
Tiger balm red 21GM	$41.1K	3
Himalaya cold balm 10GM	$33.0K	4

Jilbaab imports 66 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Moov	Brand Names & OTC Products	$152.0K	9	1.1%	11
2	Iodex	Brand Names & OTC Products	$71.9K	3	1.1%	3

Jilbaab imports 2 pharmaceutical products across 1 categories into Maldives totaling $224.0K.

Jilbaab — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Jilbaab is a pharmaceutical importer based in the Maldives, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Maldivian pharmaceutical distribution network, ensuring the availability of essential medications to meet the healthcare needs of the population. While specific details about its headquarters and parent company are not publicly disclosed, Jilbaab's operations are integral to the country's healthcare supply chain.

2Distribution Network

Jilbaab's distribution network encompasses multiple warehouse locations within the Maldives, strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported medications. Geographically, Jilbaab's coverage spans the entire Maldivian archipelago, ensuring that both urban centers and remote islands have access to necessary pharmaceutical supplies.

3Industry Role

In the Maldivian pharmaceutical supply chain, Jilbaab functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from India, the company bridges the gap between international manufacturers and local healthcare providers, ensuring a steady supply of medications across the nation. This role is crucial in maintaining the integrity and reliability of the country's pharmaceutical distribution system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Jilbaab

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Jilbaab's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a limited number of suppliers. The company's total import value from India stands at $224,000 USD, distributed across 12 shipments. The top two products imported are Moov and Iodex, accounting for 100% of the import value. This concentrated sourcing approach may pose risks related to supply chain disruptions, as any issues with these suppliers could impact Jilbaab's ability to meet market demand. However, this strategy could also reflect a deliberate choice to establish strong, long-term relationships with select suppliers, potentially leading to favorable terms and consistent product quality.

2Supply Chain Resilience

Jilbaab's supply chain resilience is closely tied to its sourcing concentration. The company's dependence on a limited number of suppliers, particularly for its top products, suggests a potential vulnerability to supply chain disruptions. The absence of backup suppliers for these key products indicates a need for strategic diversification to enhance supply chain robustness. Additionally, the company's focus on a narrow range of formulations may limit its ability to adapt to changing market demands or regulatory shifts. Ensuring that key suppliers adhere to international Good Manufacturing Practices (GMP) is essential to maintain product quality and compliance with regulatory standards.

Importing Pharmaceuticals into Maldives — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Maldives

1Regulatory Authority & Framework

The Maldives Food and Drug Authority (MFDA) is the primary regulatory body overseeing the importation, manufacture, distribution, and sale of pharmaceutical products in the Maldives. Established under the Maldives Food and Drug Authority Act (2016), the MFDA aims to protect public health by ensuring that all food and medicinal products meet established safety, efficacy, and quality standards. The Act provides a comprehensive framework for regulating pharmaceutical imports, including the registration of medicines, licensing of importers, and enforcement of Good Manufacturing Practices (GMP). The MFDA's regulations are aligned with international standards, ensuring that imported pharmaceutical products are safe and effective for the Maldivian population.

2Import Licensing & GMP

Import licensing in the Maldives is governed by the MFDA, which requires all medicine importers and sellers to be registered and licensed. To obtain an import license, companies must provide certified copies of their Business Registration Certificate, Pharmacy or Wholesale License, and Tax Registration Number. Additionally, a Product Information Sheet, structured according to the MFDA's prescribed format, must be submitted. This document should include details such as pharmaceutical form, strength, composition, therapeutic indications, dosage and administration, contraindications, warnings, adverse reactions, and pharmacodynamic and pharmacokinetic properties. Regarding GMP, the MFDA mandates that all manufacturers adhere to Good Manufacturing Procedures, and imports must be sourced from such manufacturers. This ensures that imported pharmaceutical products meet international quality standards and are safe for consumption.

Jilbaab — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Jilbaab's product strategy focuses on a narrow range of therapeutic categories, primarily importing brand-name over-the-counter (OTC) products. The company's top two imported products, Moov and Iodex, are well-known analgesic creams used for pain relief. This focus suggests a strategic alignment with market demand for effective and accessible pain management solutions. The choice to import these specific products may be driven by their established market presence and consumer trust, indicating a demand for reliable pain relief options among the Maldivian population.

2Sourcing Profile

Jilbaab's sourcing strategy is centered on importing generic drugs from India, with a particular emphasis on formulations that are well-established and widely used. The company's preference for finished pharmaceutical formulations aligns with its role as a wholesaler and distributor, facilitating efficient supply chain management and ensuring the availability of ready-to-use products in the Maldivian market. India's robust pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a suitable sourcing partner for Jilbaab's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Jilbaab

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Jilbaab's supply chain, especially if they can offer products that meet the MFDA's quality standards and align with market demand. Diversifying Jilbaab's supplier base could mitigate risks associated with supply chain disruptions and enhance the company's ability to offer a broader range of products to the Maldivian market. Identifying gaps in Jilbaab's current sourcing, such as unmet therapeutic needs or emerging market trends, could provide avenues for new suppliers to establish partnerships and expand their presence in the Maldives.

2Requirements & Qualifications

Indian exporters seeking to supply Jilbaab and the broader Maldivian market must adhere to the MFDA's regulatory requirements. This includes obtaining the necessary import licenses, ensuring that products meet GMP standards, and providing comprehensive product information sheets as specified by the MFDA. Additionally, exporters must ensure that their products comply with the MFDA's quality control measures, including batch testing, stability requirements, and labeling standards. Adhering to these regulations is essential for gaining approval to supply pharmaceutical products in the Maldives.

How to Approach

Frequently Asked Questions — Jilbaab

What products does Jilbaab import from India?

Jilbaab imports 2 pharmaceutical products across 1 categories. Top imports: Moov ($152.0K), Iodex ($71.9K).

Who supplies pharmaceuticals to Jilbaab from India?

Jilbaab sources from 2 verified Indian suppliers. The primary supplier is Krishna Marketing (99.8% of imports, $1.3M).

What is Jilbaab's total pharmaceutical import value?

Jilbaab's total pharmaceutical import value from India is $224.0K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Jilbaab focus on?

Jilbaab imports across 1 categories. The largest: Brand Names & OTC Products (100.0%).

Get Full Jilbaab Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.